Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Gilead ( GILD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole was unchanged today. By the end of trading, Gilead fell $1.20 (-2.3%) to $51.03 on average volume. Throughout the day, 10,014,910 shares of Gilead exchanged hands as compared to its average daily volume of 12,338,500 shares. The stock ranged in price between $50.82-$53.26 after having opened the day at $52.77 as compared to the previous trading day's close of $52.23. Other companies within the Drugs industry that declined today were: Amicus Therapeutics ( FOLD), down 20.4%, Oramed Pharmaceuticals ( ORMP), down 19.1%, Senesco Technologies ( SNTI), down 12.6% and Oxygen Biotherapeutics ( OXBT), down 11.2%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $79.2 billion and is part of the health care sector. The company has a P/E ratio of 29.0, above the S&P 500 P/E ratio of 17.7. Shares are up 41.5% year to date as of the close of trading on Friday. Currently there are 20 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, solid stock price performance, reasonable valuation levels and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Epizyme ( EPZM), down 10.7%, Skystar Bio-Pharmaceutical Company ( SKBI), down 10.4%, Pacific Biosciences of California ( PACB), down 9.1% and Palatin Technologies ( PTN), down 8.7% , were all gainers within the drugs industry with Illumina ( ILMN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

These Stocks Pay You to Own Them

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition